Hunter Biden’s statement that his father’s prostate cancer is causing substantial pain has renewed attention to the medical details of former President Joe Biden’s diagnosis. The discussion intensified after a Telegram channel published a video that it says shows Biden leaving Mass in Wilmington, Delaware, on Aug. 8. The footage itself is not a medical record, and its precise provenance has not been independently verified by MAIR, but the underlying cancer history is well documented.
Biden’s office announced in May 2025 that the then-82-year-old former president had an aggressive prostate cancer with a Gleason score of 9, Grade Group 5, and metastasis to bone. It also said the cancer was hormone-sensitive. Those terms describe different aspects of disease biology: tumor grade, where the cancer has spread, and whether its growth remains responsive to suppression of androgen signaling.
The Gleason score is based on how prostate cancer cells look under a microscope. The National Cancer Institute explains that Grade Group 5 corresponds to a Gleason score of 9 or 10. A higher score indicates tumor tissue that appears more abnormal and is generally associated with more aggressive behavior. It is an important prognostic feature, but it is not a stand-alone estimate of how long an individual patient will live.
Metastasis is a separate concept. Biden’s office said the cancer had spread to bone. In prostate cancer, bone is a common site of distant spread. NCI’s treatment information notes that bone metastases can produce pain and can lead to complications such as weakened bone. This makes Hunter Biden’s description of his father’s pain medically plausible without allowing outsiders to infer whether the disease has recently progressed.
Hormone-sensitive disease means that the cancer can still respond when androgen activity is reduced or blocked. Androgen-deprivation therapy, or ADT, is a core treatment for metastatic hormone-sensitive prostate cancer. Current practice often adds another hormone-directed drug and, in some cases, chemotherapy or other therapies, depending on the individual clinical situation. The term “hormone-sensitive” should not be mistaken for “mild”; it describes treatment responsiveness, not a low stage.
Biden later received hormone therapy and radiation. In July 2026, he said the treatment was going well. His office has not released detailed recent imaging, laboratory values or a new individualized prognosis. Without those data, it is not possible to determine from public information whether the cancer burden has shrunk, remained stable or changed recently.
Pain and treatment response are also not opposites. A person can have disease that is responding to therapy while still experiencing pain from existing bone lesions, inflammation, structural effects or other causes. Cancer treatments themselves can produce fatigue and other symptoms. Only the patient’s clinicians can distinguish among those possibilities in Biden’s case.
The circulated church video illustrates a common problem in public discussions of illness: the temptation to diagnose from appearance. A person with metastatic cancer may continue to walk, attend religious services and participate in selected events. None of those activities rules out serious disease. Likewise, a slow gait, weight change or tired expression would not prove progression without supporting clinical evidence.
The church context can be independently checked in part. St. Joseph on the Brandywine’s calendar lists a 5 p.m. Saturday vigil Mass on Aug. 8, and Biden has attended the parish for many years. He was independently photographed there on June 13, 2026. What has not been independently confirmed is that the specific Telegram clip was recorded on Aug. 8 or that it represented his first appearance after Hunter’s interview.
For medical readers, the key discipline is to separate what is known about the disease class from what is known about the patient. NCI guidance describes how metastatic hormone-sensitive prostate cancer is generally treated and why bone metastases may hurt. Biden’s office provides a public diagnosis and treatment history. Hunter Biden supplies a family observation about symptoms. None of these sources provides the complete dataset needed to predict Biden’s individual course.
The public record therefore supports a cautious conclusion. Joe Biden has a high-grade metastatic prostate cancer that is hormone-sensitive and has been treated with hormone therapy and radiation. His son says the illness is causing significant pain. The former president has continued to make selected public appearances. Those facts can all be true at once, and they do not, on their own, establish a new deterioration or a new stage of disease.
As with any cancer case, the most important unanswered questions — current disease burden, biomarkers, treatment regimen, treatment response and prognosis — belong to the clinical record. Unless Biden or his physicians choose to release them, they should remain unknown rather than filled in by visual inference or social-media speculation.
